Q1 FY27 results: revenue up 56 percent YoY at Rs 20.9 cr, PAT at Rs 1.1 cr

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹74.70

prior close

₹84.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%+0.9% vs market

Pharmaceuticals peers, median of 164sector+0.1%+0.7% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.8

10m

-8.1

15m

-12.1

30m

-8.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7-0.2+0.9+0.1+0.7

Next day

-0.9+0.2-1.1-0.4-0.5

-5.9+0.4-6.3+0.1-6.1

-2.3+0.4-2.8-0.4-1.9

-5.8+0.6-6.3-0.9-4.9

-4.4+0.9-5.4-0.5-4.0

-2.3+0.9-3.2-1.0-1.4

15d

+9.6+0.9+8.7-0.8+10.5

+6.7+2.3+4.3+0.9+5.7

-3.9-1.1-2.8-3.1-0.9

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Drugs reported Q1 FY27 standalone revenue of Rs 20.9 cr versus Rs 13.4 cr in Q1 FY26, up about 56 percent YoY. PAT surged to Rs 1.1 cr from Rs 11 lakh. EPS rose to Rs 0.84 from Rs 0.11. Consolidated revenue was Rs 20.9 cr with PAT of Rs 1.1 cr. Auditors Pundarikashyam and Associates issued an unqualified limited review report. Company noted over 33 percent equity dilution from a recent preferential issue, but said EPS still improved due to stronger earnings.

Likely market impact

Strong quarterly performance with sharp profit growth despite equity dilution. Clean audit report. Positive for shareholders.